Physician profile
Robert Hammons
NPI 1710990064
$813.13
in general payments reported to CMS, 2019-2025
13 companies · $14.53 in 2025
The $14.53 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.26 · 2020: $213 · 2021: $137 · 2022: $106 · 2023: $236 · 2024: $57.12 · 2025: $14.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $274.85 | 2020-2024 | Lifevest |
| Medtronic, INC. | $189.25 | 2023-2024 | Corevalve Evolut R, Octopus, Penditure |
| Boston Scientific Corporation | $146.31 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $35.80 | 2022-2024 | Repatha |
| Impulse Dynamics (USA) INC. | $33.73 | 2022 | |
| Atricure, INC. | $28.36 | 2023 | |
| Merck Sharp & Dohme LLC | $18.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.36 | 2022 | |
| Novo Nordisk INC | $14.70 | 2019 | |
| Abbott Laboratories | $14.53 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Alnylam Pharmaceuticals INC. | $14.45 | 2019 | |
| Cardiva Medical, INC. | $13.93 | 2023 | Cardiva Vascade 6/7f Vcs |
| Janssen Pharmaceuticals, INC | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hammons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.